StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — IDBI Capital

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))26 Oct 2026via IDBI Capital Research Calls Telegram

Entry₹1,305Stated
Target₹1,361
Total upside +4.29%
Stop loss₹1,277-2.15% risk
CMP₹1,310.9Just now
Active+0.45%+3.82%upside left 11d left
Follow IDBI Capital for new calls(25% target hit, 376 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 5 other Swing calls on DRREDDYSee 73 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 3:46 pm IST
5 supporting2 neutral3 opposing
Supports the BUY call (5)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

7 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 5d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 5d ago

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (2)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 2d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

MACD below its signal line — bearish momentum

Technicals · macd·26 Oct · today

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 2d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 2d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from IDBI Capital

Every call and its outcome